Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Amr Norfolk

Neither a doctor nor a teaching hospital

Research payments

$1,457,120

83 payments

Through program year 2025, Amr Norfolk is reported as receiving $1,457,120 in research payments, across 83 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $79,693 3
2024 Research $115,293 4
2023 Research $105,291 44
2022 Research $3,195 5
2021 Research $1,153,648 27

Breakdown

Who paid Research payments · program years 2021–2025
  1. Valneva Austria GmbH $1,149,655 24 payments
  2. Vertex Pharmaceuticals Incorporated $194,949 8 payments
  3. Abbott Laboratories $104,520 41 payments
  4. Pfizer Inc. $4,002 7 payments
  5. AbbVie, Inc. $3,993 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $1,106,442 18 payments
  2. i-STAT Cardiac Troponin I NxG Apparently Healthy Specimen Collection and Clinical Evaluation $104,520 41 payments
  3. A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy $101,610 5 payments
  4. A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $92,937 2 payments
  5. An Open-Label, Single Arm Study to Evaluate Antibody Persistence and Long Term Safety of A Live-Attenuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $43,213 6 payments
  6. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $3,993 3 payments
  7. A Phase 1 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age $3,195 5 payments
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $808 2 payments
  9. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $402 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record